TREATING HEREDITARY ANGIOEDEMA ATTACK WITH REDUCED DOSAGE OF ANTIBODIES BINDING TO HUMAN PLASMA KALLIKREIN

摘要

Provided herein are methods of treating and preventing hereditary angioedema attack in certain human patient subpopulations whose disease is well controlled in a first treatment period, which involves the use of an antibody that binds human plasma kallikrein. Such patients can be subject to a reduced dosage of the antibody and/or a prolonged dosing interval in a second treatment period.